Efficacy and Safety Evaluation of Immune Checkpoint Inhibitors in Combination With Chemotherapy for Extensive Small Cell Lung Cancer: Real‐World Evidence
ABSTRACT Introduction Extensive small cell lung cancer (ES‐SCLC) are currently managed using first‐line chemotherapy options, including atezolizumab (Atezo) plus etoposide and carboplatin (CE) or durvalumab (Durva) plus etoposide with either cisplatin (PE) or carboplatin (CE). However, a definitive...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-12-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.70480 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832593673376759808 |
|---|---|
| author | Yuta Yamanaka Yukiko Okuno Keisuke Kamisako Yuta Okazaki Kentaro Nakanishi Yume Sanada Kiyori Yoshida Tatsuki Ikoma Yuki Takeyasu Utae Katsushima Hiroshige Yoshioka Takayasu Kurata |
| author_facet | Yuta Yamanaka Yukiko Okuno Keisuke Kamisako Yuta Okazaki Kentaro Nakanishi Yume Sanada Kiyori Yoshida Tatsuki Ikoma Yuki Takeyasu Utae Katsushima Hiroshige Yoshioka Takayasu Kurata |
| author_sort | Yuta Yamanaka |
| collection | DOAJ |
| description | ABSTRACT Introduction Extensive small cell lung cancer (ES‐SCLC) are currently managed using first‐line chemotherapy options, including atezolizumab (Atezo) plus etoposide and carboplatin (CE) or durvalumab (Durva) plus etoposide with either cisplatin (PE) or carboplatin (CE). However, a definitive distinction in therapeutic effects between Atezo and Durva in these regimens remains unestablished. Methods We analyzed data from 100 patients diagnosed with ES‐SCLC who received immune checkpoint inhibitors (ICIs) as first‐line chemotherapy. Among them, 70 were administered Atezo + CE, 12 received Durva + PE, and 18 received Durva + CE. We assessed the efficacy of the two ICIs across various factors. Results The progression‐free survival (PFS) and overall survival (OS) did not significantly differ between Atezo + CE and Durva + CE/PE as first‐line chemotherapy treatments for SCLC. We observed no significant differences in age, sex, performance status (PS), liver metastasis, bone metastasis, or platinum‐based agent usage between the treatment cohorts. However, a marked improvement in PFS and OS was observed in the solitary patient with brain metastasis treated with Atezo + CE. Conclusion The primary distinction between these treatments was observed in the management of patients with brain metastasis. The literature lacks comparative studies on the effects of first‐line ICI treatment on the central nervous system, rendering our findings significant in clinical practice. Despite the retrospective nature of this study and the potential for various biases, we recommend the preferential use of Atezo + CE in patients with brain metastasis to potentially enhance prognosis. |
| format | Article |
| id | doaj-art-3e3fc08f7e1246a39a2d0914d2f99d07 |
| institution | Kabale University |
| issn | 2045-7634 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-3e3fc08f7e1246a39a2d0914d2f99d072025-01-20T10:51:32ZengWileyCancer Medicine2045-76342024-12-011324n/an/a10.1002/cam4.70480Efficacy and Safety Evaluation of Immune Checkpoint Inhibitors in Combination With Chemotherapy for Extensive Small Cell Lung Cancer: Real‐World EvidenceYuta Yamanaka0Yukiko Okuno1Keisuke Kamisako2Yuta Okazaki3Kentaro Nakanishi4Yume Sanada5Kiyori Yoshida6Tatsuki Ikoma7Yuki Takeyasu8Utae Katsushima9Hiroshige Yoshioka10Takayasu Kurata11Department of Thoracic Oncology Kansai Medical University Hospital Osaka JapanDepartment of Thoracic Oncology Kansai Medical University Hospital Osaka JapanDepartment of Thoracic Oncology Kansai Medical University Hospital Osaka JapanDepartment of Thoracic Oncology Kansai Medical University Hospital Osaka JapanDepartment of Thoracic Oncology Kansai Medical University Hospital Osaka JapanDepartment of Thoracic Oncology Kansai Medical University Hospital Osaka JapanDepartment of Thoracic Oncology Kansai Medical University Hospital Osaka JapanDepartment of Thoracic Oncology Kansai Medical University Hospital Osaka JapanDepartment of Thoracic Oncology Kansai Medical University Hospital Osaka JapanDepartment of Thoracic Oncology Kansai Medical University Hospital Osaka JapanDepartment of Thoracic Oncology Kansai Medical University Hospital Osaka JapanDepartment of Thoracic Oncology Kansai Medical University Hospital Osaka JapanABSTRACT Introduction Extensive small cell lung cancer (ES‐SCLC) are currently managed using first‐line chemotherapy options, including atezolizumab (Atezo) plus etoposide and carboplatin (CE) or durvalumab (Durva) plus etoposide with either cisplatin (PE) or carboplatin (CE). However, a definitive distinction in therapeutic effects between Atezo and Durva in these regimens remains unestablished. Methods We analyzed data from 100 patients diagnosed with ES‐SCLC who received immune checkpoint inhibitors (ICIs) as first‐line chemotherapy. Among them, 70 were administered Atezo + CE, 12 received Durva + PE, and 18 received Durva + CE. We assessed the efficacy of the two ICIs across various factors. Results The progression‐free survival (PFS) and overall survival (OS) did not significantly differ between Atezo + CE and Durva + CE/PE as first‐line chemotherapy treatments for SCLC. We observed no significant differences in age, sex, performance status (PS), liver metastasis, bone metastasis, or platinum‐based agent usage between the treatment cohorts. However, a marked improvement in PFS and OS was observed in the solitary patient with brain metastasis treated with Atezo + CE. Conclusion The primary distinction between these treatments was observed in the management of patients with brain metastasis. The literature lacks comparative studies on the effects of first‐line ICI treatment on the central nervous system, rendering our findings significant in clinical practice. Despite the retrospective nature of this study and the potential for various biases, we recommend the preferential use of Atezo + CE in patients with brain metastasis to potentially enhance prognosis.https://doi.org/10.1002/cam4.70480atezolizumabdurvalumabextensive‐stage small cell lung cancerfirst‐line treatmentimmune checkpoint blockadereal‐world evidence |
| spellingShingle | Yuta Yamanaka Yukiko Okuno Keisuke Kamisako Yuta Okazaki Kentaro Nakanishi Yume Sanada Kiyori Yoshida Tatsuki Ikoma Yuki Takeyasu Utae Katsushima Hiroshige Yoshioka Takayasu Kurata Efficacy and Safety Evaluation of Immune Checkpoint Inhibitors in Combination With Chemotherapy for Extensive Small Cell Lung Cancer: Real‐World Evidence Cancer Medicine atezolizumab durvalumab extensive‐stage small cell lung cancer first‐line treatment immune checkpoint blockade real‐world evidence |
| title | Efficacy and Safety Evaluation of Immune Checkpoint Inhibitors in Combination With Chemotherapy for Extensive Small Cell Lung Cancer: Real‐World Evidence |
| title_full | Efficacy and Safety Evaluation of Immune Checkpoint Inhibitors in Combination With Chemotherapy for Extensive Small Cell Lung Cancer: Real‐World Evidence |
| title_fullStr | Efficacy and Safety Evaluation of Immune Checkpoint Inhibitors in Combination With Chemotherapy for Extensive Small Cell Lung Cancer: Real‐World Evidence |
| title_full_unstemmed | Efficacy and Safety Evaluation of Immune Checkpoint Inhibitors in Combination With Chemotherapy for Extensive Small Cell Lung Cancer: Real‐World Evidence |
| title_short | Efficacy and Safety Evaluation of Immune Checkpoint Inhibitors in Combination With Chemotherapy for Extensive Small Cell Lung Cancer: Real‐World Evidence |
| title_sort | efficacy and safety evaluation of immune checkpoint inhibitors in combination with chemotherapy for extensive small cell lung cancer real world evidence |
| topic | atezolizumab durvalumab extensive‐stage small cell lung cancer first‐line treatment immune checkpoint blockade real‐world evidence |
| url | https://doi.org/10.1002/cam4.70480 |
| work_keys_str_mv | AT yutayamanaka efficacyandsafetyevaluationofimmunecheckpointinhibitorsincombinationwithchemotherapyforextensivesmallcelllungcancerrealworldevidence AT yukikookuno efficacyandsafetyevaluationofimmunecheckpointinhibitorsincombinationwithchemotherapyforextensivesmallcelllungcancerrealworldevidence AT keisukekamisako efficacyandsafetyevaluationofimmunecheckpointinhibitorsincombinationwithchemotherapyforextensivesmallcelllungcancerrealworldevidence AT yutaokazaki efficacyandsafetyevaluationofimmunecheckpointinhibitorsincombinationwithchemotherapyforextensivesmallcelllungcancerrealworldevidence AT kentaronakanishi efficacyandsafetyevaluationofimmunecheckpointinhibitorsincombinationwithchemotherapyforextensivesmallcelllungcancerrealworldevidence AT yumesanada efficacyandsafetyevaluationofimmunecheckpointinhibitorsincombinationwithchemotherapyforextensivesmallcelllungcancerrealworldevidence AT kiyoriyoshida efficacyandsafetyevaluationofimmunecheckpointinhibitorsincombinationwithchemotherapyforextensivesmallcelllungcancerrealworldevidence AT tatsukiikoma efficacyandsafetyevaluationofimmunecheckpointinhibitorsincombinationwithchemotherapyforextensivesmallcelllungcancerrealworldevidence AT yukitakeyasu efficacyandsafetyevaluationofimmunecheckpointinhibitorsincombinationwithchemotherapyforextensivesmallcelllungcancerrealworldevidence AT utaekatsushima efficacyandsafetyevaluationofimmunecheckpointinhibitorsincombinationwithchemotherapyforextensivesmallcelllungcancerrealworldevidence AT hiroshigeyoshioka efficacyandsafetyevaluationofimmunecheckpointinhibitorsincombinationwithchemotherapyforextensivesmallcelllungcancerrealworldevidence AT takayasukurata efficacyandsafetyevaluationofimmunecheckpointinhibitorsincombinationwithchemotherapyforextensivesmallcelllungcancerrealworldevidence |